CADTH Canadian Drug Expert Committee final recommendation: Canagliflozin and metformin hydrochloride (Invokamet -- Janssen Inc.) : type 2 diabetes mellitus
The CADTH Canadian Drug Expert Committee (CDEC) recommends that canagliflozin and metformin hydrochloride (canagliflozin/metformin) be reimbursed for patients with type 2 diabetes mellitus provided that criterion and condition are met
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, August 25, 2016
|
Series: | Common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that canagliflozin and metformin hydrochloride (canagliflozin/metformin) be reimbursed for patients with type 2 diabetes mellitus provided that criterion and condition are met |
---|---|
Physical Description: | 1 PDF file (5 pages) |